Neil Kumar, a director and officer of BridgeBio Pharma, Inc., filed a Form 144 notice on November 18, 2026, disclosing a proposed sale of 34,980 shares of common stock on NASDAQ under a Rule 10b5-1 plan.
Key Highlights
- Proposed sale: Neil Kumar intends to sell 34,980 shares of BridgeBio Pharma common stock with an aggregate market value of $2,686,464.00.
- Source of shares: The shares were acquired on November 16, 2026, via restricted stock units granted by the issuer.
- Broker: The sale is to be conducted through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.
- 10b5-1 plan date: The plan under which the sale is proposed was adopted on May 13, 2026.
- Shares outstanding: According to the filing, 194,800,782 shares of common stock were outstanding at the time of the notice.
- Prior sales in past 3 months: Kumar sold 36,236 shares on November 16, 2026, for gross proceeds of $2,803,216.96, and the Kumar Haldea Family Irrevocable Trust sold 10,000 shares on September 17, 2026, for $690,847.00, and 10,000 shares on August 19, 2026, for $840,258.00.
BridgeBio Pharma Director and Officer Neil Kumar Files Rule 144 Sale Notice
According to the Form 144 filing dated November 18, 2026, Neil Kumar, identified as both a director and an officer of BridgeBio Pharma, Inc. (NASDAQ:BBIO), proposes to sell 34,980 shares of the company's common stock. The filing lists an approximate sale date of November 18, 2026, and states an aggregate market value of $2,686,464.00 for the shares to be sold. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services.
The filing discloses that the 34,980 shares were acquired on November 16, 2026, through restricted stock units issued by the company, with payment described as "N/A." The notice indicates the sale is being conducted in reliance on a Rule 10b5-1 trading plan adopted on May 13, 2026. The filing also shows that Kumar personally sold 36,236 shares of common stock on November 16, 2026, generating gross proceeds of $2,803,216.96, within the three months preceding this notice.
Additionally, the filing reports prior sales attributed to the Kumar Haldea Family Irrevocable Trust dated 05/18/2019, also listed at the same Palo Alto, California address: 10,000 shares sold on September 17, 2026, for gross proceeds of $690,847.00, and 10,000 shares sold on August 19, 2026, for gross proceeds of $840,258.00. Both of those transactions are described as 10b5-1 sales. The filing was signed by Neil Kumar, who represented that he does not know of any material adverse information regarding BridgeBio Pharma's current and prospective operations that has not been publicly disclosed.
What Was Disclosed
Neil Kumar, a director and officer of BridgeBio Pharma, Inc., filed a Form 144 on November 18, 2026, proposing to sell 34,980 shares of common stock worth $2,686,464.00, acquired via restricted stock units on November 16, 2026, under a 10b5-1 plan adopted May 13, 2026.




Please wait processing your request...